HB 2486 Summary

• Appropriates $30,000,000 from the state general fund in fiscal year 2023-2024 to the Department of Health Services for competitive psilocybin research grants.

• Funds whole mushroom psilocybin phase one, two, and three clinical trials capable of FDA approval to evaluate treatment of PTSD, long COVID-19, depression, anxiety, end-of-life distress, OCD, substance abuse, eating disorders, chronic pain, inflammatory disorders, autoimmune disorders, seizure disorders, and degenerative disorders.

• Prioritizes clinical trials using psilocybin cultivated under a DEA schedule I license and prioritizes research subjects from veteran, first responder, frontline healthcare worker, and underserved communities.

• Establishes a psilocybin research advisory council within the Department of Health Services composed of the director and four appointed members, tasked with establishing clinical trial criteria, reviewing grant applications, conducting public meetings, and making annual recommendations on psychedelic-assisted therapy policy.

• Provides immunity from prosecution under title 13, chapter 34 for grant recipients and their employees working on authorized psilocybin clinical trials; article 5 repeals automatically on December 31, 2028.